Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | SLC10A1 | Q14973 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.37 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.37 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | WRN | Q14191 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21727654 | 0.90 | GRM4 (0.47) | GRM4CA9CA12SLC10A1CA2 | |
| SCHEMBL16257263 | 0.87 | GRM4 (0.44) | GRM4SLC10A1ABCC9ABCC8KCNJ11 | |
| SCHEMBL16257185 | 0.86 | GRM4 (0.43) | GRM4SLC10A1ABCC9ABCC8KCNJ11 | |
| SCHEMBL17700898 | 0.85 | GRM4 (0.41) | GRM4SLC10A1ABCC9ABCC8KCNJ11 | |
| SCHEMBL17700964 | 0.85 | GRM4 (0.41) | GRM4SLC10A1ABCC9ABCC8KCNJ11 | |
| SCHEMBL21727506 | 0.84 | GRM4 (0.42) | GRM4SLC10A1ABCC9ABCC8KCNJ11 | |
| SCHEMBL18407949 | 0.83 | GRM4 (0.41) | GRM4SLC10A1ABCC9ABCC8KCNJ11 | |
| SCHEMBL17700686 | 0.83 | GRM4 (0.41) | GRM4SLC10A1PGRAR | |
| SCHEMBL16257389 | 0.83 | GRM4 (0.41) | GRM4SLC10A1ABCC9ABCC8KCNJ11 | |
| SCHEMBL16257319 | 0.83 | GRM4 (0.41) | GRM4SLC10A1ABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121164-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-02-19 | — | — | EP | disclosed |
| US-10457638-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457638-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | RB1, XDH, HBS1L | GRM4 2826/4885CA9 2637/4885CA12 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.